NASA's Red Light Therapy Research: The Origin Story

Red light therapy is routinely marketed as “NASA technology” or “NASA-approved.” Whilst the space agency genuinely funded some of the earliest research into LED photobiomodulation, the reality is more nuanced — and more interesting — than the marketing suggests.

This page traces the real history: the original problem NASA needed to solve, the researchers who did the work, the published results, and how those findings shaped a multi-billion-pound industry.

The Problem: Wound Healing in Microgravity

When astronauts spend extended periods in space, their bodies change in ways that complicate medical care. Microgravity impairs wound healing, reduces bone density, causes muscle atrophy, and suppresses immune function. Minor injuries that would heal uneventfully on Earth become genuine concerns on long-duration missions.

By the early 1990s, NASA recognised that any serious effort at sustained human spaceflight — whether aboard the International Space Station or on future Mars missions — needed solutions to these physiological challenges. Surgery in space was impractical. Pharmacological approaches had weight and storage limitations. NASA needed something compact, energy-efficient, and capable of accelerating tissue repair without consumable supplies.

That search led to an unexpected place: light-emitting diodes.

The Quantum Devices Connection

The story begins not in a NASA laboratory, but at a small company in Barneveld, Wisconsin called Quantum Devices, Inc. Founded by Ron Ignatius, the company initially manufactured high-intensity LEDs for commercial and industrial use.

In the late 1980s, Quantum Devices was already developing LED arrays for plant growth experiments aboard the Space Shuttle — the Astroculture programme. NASA needed artificial light sources that could sustain plant photosynthesis in orbit, and LEDs offered advantages over traditional lamps: lower heat output, longer lifespan, and narrower spectral control.

During this work, researchers noticed something unexpected. Technicians handling the LED arrays reported that minor cuts and abrasions on their hands seemed to heal faster than usual. This anecdotal observation — hardly rigorous science — nevertheless caught the attention of NASA programme managers, who saw a potential dual-use application.

If LEDs could accelerate plant growth through targeted wavelengths of light, could they do something similar for human tissue?

Harry Whelan and the Medical College of Wisconsin

To answer that question rigorously, NASA turned to Dr Harry T. Whelan, a paediatric neurologist and researcher at the Medical College of Wisconsin (MCW) in Milwaukee. Whelan had expertise in both neurology and phototherapy, making him an ideal collaborator.

Beginning in the mid-1990s, NASA funded a series of studies through its Marshall Space Flight Centre in Huntsville, Alabama. The work was conducted primarily by Whelan’s team at MCW, with LED hardware supplied by Quantum Devices.

The Key Research Programme

The NASA-funded research programme at MCW ran from approximately 1995 through the mid-2000s. It produced several landmark publications:

Whelan et al. (2001) — “Effect of NASA Light-Emitting Diode Irradiation on Wound Healing” Published in the Journal of Clinical Laser Medicine & Surgery, this study examined the effects of 670nm, 728nm, and 880nm LED irradiation on wound healing in a murine model (PMID: 11706695). The results demonstrated a significant acceleration in wound closure: LED-treated wounds showed approximately 40% faster healing compared to untreated controls. Notably, the 670nm wavelength proved particularly effective.

Whelan et al. (2002) — “NASA Light Emitting Diode Medical Applications: From Deep Space to Deep Sea to Doctor’s Office” This review, published in Space Technology and Applications International Forum, provided a comprehensive overview of NASA’s LED phototherapy programme. It documented the rationale for LED-based phototherapy, the transition from plant-growth research to medical applications, and preliminary clinical results across multiple tissue types.

Whelan et al. (2003) — “Effect of NASA Light-Emitting Diode Irradiation on Molecular Changes for Wound Healing in Diabetic Mice” Published in the Journal of Clinical Laser Medicine & Surgery (PMID: 12737635), this study examined LED effects on the molecular mechanisms of wound healing in diabetic models — a population with notoriously impaired wound repair. Results showed increased expression of genes involved in mitochondrial energy metabolism and antioxidant defence.

Desmet et al. (2006) — “Clinical and Experimental Applications of NIR-LED Photobiomodulation” Published in Photomedicine and Laser Surgery (PMID: 16706694), this paper reviewed both NASA-funded research and broader clinical applications of near-infrared LED therapy, documenting effects on wound healing, musculoskeletal conditions, and neurological applications.

What the Studies Actually Found

Across the NASA-funded programme, the key findings were:

Accelerated wound healing. LED irradiation at 670nm and 880nm consistently improved wound closure rates in animal models, typically by 40-50% compared to controls.
Cellular energy production. LED light at these wavelengths increased mitochondrial cytochrome c oxidase activity — the same mechanism now understood to underpin photobiomodulation more broadly. Cells exposed to LED irradiation produced more adenosine triphosphate (ATP), the fundamental energy currency of cellular metabolism.
Gene expression changes. LED exposure upregulated genes involved in cellular proliferation, antioxidant protection, and extracellular matrix production — all critical for effective wound repair.
Fibroblast proliferation. Human fibroblast cultures exposed to LED irradiation showed growth rates 140-200% above untreated controls, depending on wavelength and dose.
Safety profile. No adverse effects were observed at the energy densities used (typically 1-50 mW/cm² irradiance, 4-50 J/cm² fluence).

The Oral Mucositis Breakthrough

Perhaps the most clinically significant outcome of NASA-funded LED research involved an application far removed from space medicine: oral mucositis in paediatric cancer patients.

Oral mucositis — painful inflammation and ulceration of the mouth lining — is a common and debilitating side effect of bone marrow transplant conditioning regimens. It causes severe pain, difficulty eating, risk of infection, and prolonged hospitalisation. Conventional management is largely supportive: pain relief, nutritional support, and time.

Whelan’s team conducted a clinical trial using 670nm LED arrays on paediatric patients undergoing bone marrow transplants at MCW. The results, published in Journal of Clinical Laser Medicine & Surgery in 2002 (PMID: 12513918), showed a 47% reduction in reported pain compared to the placebo group, along with reduced severity and duration of mucositis lesions.

This was a genuinely important finding. It demonstrated that LED photobiomodulation could produce clinically meaningful results in a well-controlled human trial — not just laboratory dishes or animal models. It remains one of the strongest individual pieces of evidence supporting photobiomodulation therapy, and has been reinforced by subsequent research and meta-analyses confirming PBM’s efficacy for oral mucositis management (PMID: 24131762).

How NASA’s Research Legitimised Photobiomodulation

Before the NASA-funded programme, photobiomodulation had a credibility problem. Research into low-level laser therapy (LLLT) had been ongoing since the late 1960s — largely driven by the work of Endre Mester in Hungary — but it occupied a fringe position in mainstream medicine. Study quality was often poor, mechanisms were poorly understood, and the field lacked institutional backing.

NASA’s involvement changed the calculus in several ways:

Institutional credibility. Having NASA’s name attached to research — however indirectly — gave the field legitimacy it had previously lacked. Funding from a major government agency signalled that the basic science was worth investigating seriously.

LED vs laser. Earlier photobiomodulation research had focused almost exclusively on lasers. The NASA programme demonstrated that LEDs — cheaper, safer, and easier to scale — could produce equivalent biological effects. This opened the door to consumer devices, since LEDs did not carry the regulatory burden or safety risks associated with lasers.

Mechanistic clarity. The MCW research contributed to a growing understanding of how photobiomodulation works at the cellular level, particularly the role of cytochrome c oxidase as the primary chromophore. Tiina Karu’s earlier work in Russia had proposed this mechanism; the NASA-funded studies provided additional supporting evidence.

Clinical translation. The oral mucositis trial demonstrated that LED therapy could pass the most important test in medicine: helping real patients in a controlled clinical setting.

From Space Research to Consumer Products

The transition from NASA-funded laboratory research to the consumer red light therapy market happened gradually, but accelerated sharply after 2010.

Several factors drove this transition:

LED costs plummeted. Advances in semiconductor manufacturing made high-power LEDs dramatically cheaper. Wavelength-specific LEDs that cost hundreds of pounds in the 1990s became commodity components costing pennies.
Patents expired. Quantum Devices held patents on certain LED array configurations for medical use. As these expired, competitors entered the market.
Research expanded. Independent research groups worldwide — building on the foundation laid by the NASA programme — published hundreds of studies on photobiomodulation across diverse applications: skin rejuvenation, pain management, cognitive function, hair growth, and more.
Direct-to-consumer marketing. Companies like Joovv, PlatinumLED, and Mito Red Light began selling LED panels directly to consumers, often invoking NASA’s research in their marketing materials.

The “NASA-Approved” Problem

Here is where the story requires careful distinction. Many red light therapy companies market their products as “NASA technology” or imply NASA endorsement. This is misleading for several reasons:

NASA funded research, not products. NASA provided grants to study LED photobiomodulation. It did not develop, test, certify, or endorse any consumer device. The research was conducted by university scientists using prototype equipment built by Quantum Devices — not by NASA engineers.

The wavelengths studied were specific. NASA-funded research focused primarily on 670nm and 880nm LEDs. Many consumer devices use different wavelengths (commonly 660nm and 850nm). Whilst these are close, they are not identical, and the NASA research does not automatically validate devices using different specifications.

Power densities and protocols differ. The treatment parameters used in NASA-funded studies (irradiance, exposure time, distance) do not necessarily match those delivered by consumer panels. A device that emits the “right” wavelength at the wrong power density will not replicate the research results.

NASA has no consumer device approval programme. Unlike the FDA, NASA does not approve or certify consumer health products. Any suggestion of “NASA approval” is simply false.

When a company claims its product uses “NASA technology,” the honest version of that claim is: “Our device uses LEDs that emit wavelengths similar to those studied in NASA-funded research conducted in the late 1990s and early 2000s.” That is a weaker — but truthful — statement.

The Broader Impact

Despite the marketing misuse, NASA’s contribution to the photobiomodulation field was genuine and significant. The NASA-funded programme:

Demonstrated that inexpensive LEDs could produce the same biological effects as expensive medical lasers
Provided some of the first rigorous evidence for wound healing acceleration via LED light
Produced a landmark clinical trial in oral mucositis that remains influential today
Gave institutional legitimacy to a field that had been marginalised for decades
Directly contributed to the mechanistic understanding of photobiomodulation via cytochrome c oxidase

The International Space Station subsequently carried LED-based phototherapy equipment for crew use, validating the practical application of the research. And the broader field of photobiomodulation — now with over 6,000 published studies — owes a meaningful debt to those early NASA-funded experiments in Wisconsin.

Key Takeaways

NASA funded LED photobiomodulation research from the mid-1990s through the early 2000s, primarily through Dr Harry Whelan’s laboratory at the Medical College of Wisconsin
The research originated from LED plant-growth experiments aboard the Space Shuttle and observations of faster wound healing
Key findings included 40-50% acceleration of wound healing, increased cellular energy production, and a landmark clinical trial showing 47% pain reduction in oral mucositis
The research legitimised LEDs as a photobiomodulation tool and helped establish the mechanistic basis for the field
“NASA-approved” marketing claims for consumer devices are misleading — NASA funded research, it did not develop or endorse any consumer product
The wavelengths, power densities, and protocols used in NASA research do not automatically transfer to consumer devices using different specifications

References

Whelan HT, et al. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg. 2001;19(6):305-314. PMID: 11706695
Whelan HT, et al. Effect of NASA light-emitting diode irradiation on molecular changes for wound healing in diabetic mice. J Clin Laser Med Surg. 2003;21(2):67-74. PMID: 12737635
Whelan HT, et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg. 2002;20(6):319-324. PMID: 12513918
Desmet KD, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24(2):121-128. PMID: 16706694
Bjordal JM, et al. A systematic review with procedural assessments and meta-analysis of low level laser therapy in lateral elbow tendinopathy. BMC Musculoskelet Disord. 2008;9:75. PMID: 18510742
Oberoi S, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107418. PMID: 24131762
Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID: 28748217